SAB Biotherapeutics (SABS) Depreciation & Amortization (CF) (2021 - 2026)
SAB Biotherapeutics (SABS) posted Depreciation & Amortization (CF) of $700000.0 for Q1 2026, down 6.27% on a QoQ basis from $746830.0 in Q4 2025, and down 12.5% year-over-year from $800000.0 in Q1 2025.
SAB Biotherapeutics (SABS) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
SAB Biotherapeutics' Depreciation & Amortization (CF) history runs 6 years deep, the most recent figure standing at $700000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 12.5% year-over-year to $700000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 15.8% YoY) and the FY2025 annual result came in at $3.0 million, down 36.17% from the prior year.
- Depreciation & Amortization (CF) was $700000.0 for Q1 2026 at SAB Biotherapeutics, down from $746830.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $2.0 million in Q1 2024 and bottomed at $636000.0 in Q1 2022.
- A 5-year average of $904899.9 and a median of $890000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 189.7% — and 2025, when it tumbled 59.25%.
- SAB Biotherapeutics' Depreciation & Amortization (CF) stood at $899429.0 in 2022, then advanced by 11.18% to $1.0 million in 2023, then declined by 20.0% to $800000.0 in 2024, then slipped by 6.65% to $746830.0 in 2025, then dropped by 6.27% to $700000.0 in 2026.
- Business Quant data shows SABS's Depreciation & Amortization (CF) at $700000.0 in Q1 2026, $746830.0 in Q4 2025, and $700000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | 700,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 700,000.00 |
| Mar 31, 2026 | 700,000.00 |
| Dec 31, 2025 | 746,830.00 |
| Dec 31, 2025 | 746,830.00 |
| Sep 30, 2025 | 700,000.00 |
| Sep 30, 2025 | 700,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Dec 31, 2024 | 800,000.00 |
| Dec 31, 2024 | 800,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.96 Mn |
| Mar 31, 2024 | 1.96 Mn |
| Dec 31, 2023 | 1.00 Mn |
| Dec 31, 2023 | 1.00 Mn |